Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

Non-Small Cell Lung Cancer Clinical Trial

Official title:

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01387269
• Other study ID #: HT-ANAM-301
• Status: Completed
• Phase: Phase 3
• First received: June 30, 2011
• Last updated: September 26, 2017
• Start date: July 2011
• Est. completion date: February 2015

Study information

• Verified date: September 2017
• Source: Helsinn Therapeutics (U.S.), Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.

Description:

This is a randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of Anamorelin in patients with non-small cell lung cancer-cachexia (NSCLC-C). The primary efficacy analysis will include the treatment difference in the change in lean body mass and physical function. Pharmacokinetic (PK) samples will also be collected at Day 43 visit for population PK.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 484
• Est. completion date: February 2015
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Documented diagnosis of unresectable Stage III or Stage IV NSCLC

• Patients may be receiving maintenance chemotherapy

• Patients planning to initiate a new chemotherapy and/or radiation therapy regimen may do so only within ± 14 days of randomization

• Patients may have completed a chemotherapy and/or radiation therapy and/or have no plan to initiate a new regimen within 12 weeks from randomization; at least 14 days must elapse from the completion of the chemotherapy and/or radiation therapy prior to randomization

• Involuntary weight loss of =5% body weight within 6 months prior to screening or a screening body mass index (BMI) <20 kg/m2

• Body mass index =30 kg/m2

• Life expectancy of >4 months at time of screening

• ECOG performance status =2

• Adequate hepatic function, defined as AST and ALT levels =5 x upper limit of normal

• Adequate renal function, defined as creatinine =2 x upper limit of normal, or calculated creatinine clearance >30 ml/minute

• Ability to understand and comply with the procedures for the HGS evaluation

• If a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 30 days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method)

• Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures

Exclusion Criteria:

• Other forms of lung cancer (e.g., small cell, mesothelioma)

• Women who are pregnant or breast-feeding

• Known HIV, hepatitis (B&C), or active tuberculosis

• Had major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization; patients must be well recovered from acute effects of surgery prior to screening; patients should not have plans to undergo major surgical procedures during the treatment period

• Currently taking prescription medications intended to increase appetite or treat weight loss; these include, but are not limited to, testosterone, androgenic compounds, megestrol acetate, methylphenidate, and dronabinol

• Inability to readily swallow oral tablets; patients with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption, or obstructive symptoms) or intractable or frequent vomiting are excluded

• Has an active, uncontrolled infection

• Has uncontrolled diabetes mellitus

• Has untreated clinically relevant hypothyroidism

• Has known or symptomatic brain metastases

• Receiving strong CYP3A4 inhibitors within 14 days of randomization

• Receiving tube feedings or parenteral nutrition (either total or partial); patients must have discontinued these treatments for at least 6 weeks prior to Day 1, and throughout the study duration

• Other clinical diagnosis, ongoing or intercurrent illness that in the Investigator's opinion would prevent the patient's participation

• Has had previous exposure to Anamorelin HCl

• Patients actively receiving a concurrent investigational agent

Related Conditions & MeSH terms

• Cachexia
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• Anamorelin HCl
Anamorelin HCl will be orally administered daily at least one hour before meal
• Placebo
Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Helsinn Therapeutics (U.S.), Inc

Countries where clinical trial is conducted

United States,  Belarus,  Belgium,  Canada,  Czechia,  France,  Germany,  Hungary,  Italy,  Netherlands,  Poland,  Russian Federation,  Serbia,  Slovenia,  Spain,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Lean Body Mass	Change in Lean Body Mass (LBM) from baseline over 12 weeks for the ITT Population. Change from baseline over 12 weeks was defined as the average of the change from baseline at Week 6 and the change from baseline at Week 12.	Change in Lean Body Mass from Baseline Over 12 Weeks
Primary	Change in Handgrip Strength	Change in Handgrip Strength (HGS) of the non-dominant hand from baseline over 12 weeks for the ITT Population. Change from baseline over 12 weeks was defined as the average of the change from baseline at Week 6 and the change from baseline at Week 12.	Change in Handgrip Strength of the Non-Dominant Hand from Baseline Over 12 Weeks
Secondary	Change in A/CS Domain Score	The Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Additional Concerns Subscale (A/CS domain) is a 12-item scale that is part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Each item is answered on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much).; The 12-items are summed together to obtain the domain score. Note that negatively phrased questions are reverse scored so that higher scores always represent improvement/less symptom burden. The total possible score for the A/CS domain ranges from 0 (worst) to 48 (best).	Change in FAACT A/CS Domain Score from Baseline Over 12 Weeks
Secondary	Change in FACIT-F Fatigue Domain Score	The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue domain is a 13-item scale that is part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Each item is answered on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much).; The 13-items are summed together to obtain the domain score. Note that negatively phrased questions are reverse scored so that higher scores always represent improvement/less symptom burden. The total possible score for the FACIT-F fatigue domain ranges from 0 (worst) to 52 (best).	Change in FACIT-F Fatigue Domain Score from Baseline Over 12 Weeks
Secondary	Change in Body Weight	Change in body weight (BW) from baseline overall (i.e., over 12 weeks) for the MITT Population.	Change in Body Weight from Baseline Over 12 Weeks